Ian Jun Yan Wee1, Hai Man Cao2, James Chi-Yong Ngu3. 1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Faculty of Medicine, University of New South Wales, Sydney, Australia. 3. Department of General Surgery, Changi General Hospital, Singapore, Singapore. ngu.chi.yong@singhealth.com.sg.
Abstract
BACKGROUND: This systematic review and meta-analysis seek to evaluate the prevalence of nodal disease in rectal cancer patients with pathological complete responses (pCR) after neoadjuvant chemoradiotherapy (ypT0N+). METHODS: This study conformed to the PRISMA guidelines. A search was performed on major databases to identify relevant articles. Meta-analyses of pooled proportions were performed on rectal cancer with pCR and ypT0N+. Meta-regression was undertaken to identify sources of heterogeneity, and the Newcastle-Ottawa Scale (NOS) was employed to assess the risk of bias. RESULTS: A total of 18 studies were included, totaling 7568 patients. The overall risk of bias was low, since all studies scored 6 and above out of 9 on the NOS. Preoperatively, the pooled proportions of patients with T3/T4 tumors and clinically positive nodal disease were 84.08% (95% CI 74.19 to 91.99%) and 52.14% (95% CI 35.02 to 69.00%) respectively. The prevalence of pCR in the whole pool was 18.52% (95% CI 13.31 to 24.35%; I2 = 93.85%; P = 0.00), and meta-regression showed a significantly negative relationship with patient age (β = - 0.03, 95% CI - 0.03 to - 0.02; P = 0.00). The pooled prevalence of ypT0N+ was 4.61% (95% CI 2.41 to 7.28%; I2 = 52.27%; P = 0.01), and meta-regression demonstrated a significantly positive relationship with male gender (β = 1.06, 95% CI 1.00 to 1.12; P = 0.04). CONCLUSION: There is a small risk of ypN+ in patients with pCR after neoadjuvant CRT and surgery for rectal cancer. However, further research is warranted to establish these findings and to identify predictive factors for this specific group of patients.
BACKGROUND: This systematic review and meta-analysis seek to evaluate the prevalence of nodal disease in rectal cancerpatients with pathological complete responses (pCR) after neoadjuvant chemoradiotherapy (ypT0N+). METHODS: This study conformed to the PRISMA guidelines. A search was performed on major databases to identify relevant articles. Meta-analyses of pooled proportions were performed on rectal cancer with pCR and ypT0N+. Meta-regression was undertaken to identify sources of heterogeneity, and the Newcastle-Ottawa Scale (NOS) was employed to assess the risk of bias. RESULTS: A total of 18 studies were included, totaling 7568 patients. The overall risk of bias was low, since all studies scored 6 and above out of 9 on the NOS. Preoperatively, the pooled proportions of patients with T3/T4 tumors and clinically positive nodal disease were 84.08% (95% CI 74.19 to 91.99%) and 52.14% (95% CI 35.02 to 69.00%) respectively. The prevalence of pCR in the whole pool was 18.52% (95% CI 13.31 to 24.35%; I2 = 93.85%; P = 0.00), and meta-regression showed a significantly negative relationship with patient age (β = - 0.03, 95% CI - 0.03 to - 0.02; P = 0.00). The pooled prevalence of ypT0N+ was 4.61% (95% CI 2.41 to 7.28%; I2 = 52.27%; P = 0.01), and meta-regression demonstrated a significantly positive relationship with male gender (β = 1.06, 95% CI 1.00 to 1.12; P = 0.04). CONCLUSION: There is a small risk of ypN+ in patients with pCR after neoadjuvant CRT and surgery for rectal cancer. However, further research is warranted to establish these findings and to identify predictive factors for this specific group of patients.
Entities:
Keywords:
Neoadjuvant chemoradiation; Nodal disease; Pathological complete response; Rectal cancer surgery
Authors: Thilo Sprenger; Hilka Rothe; Lena-Christin Conradi; Tim Beissbarth; Anne Kauffels; Julia Kitz; Kia Homayounfar; Hendrik Wolff; Philipp Ströbel; Michael Ghadimi; Christian Wittekind; Rolf Sauer; Claus Rödel; Torsten Liersch Journal: Dis Colon Rectum Date: 2016-05 Impact factor: 4.585
Authors: Krzysztof Bujko; Milena Kolodziejczyk; Anna Nasierowska-Guttmejer; Wojciech Michalski; Lucyna Kepka; Ewa Chmielik; Andrzej Wojnar; Maciej Chwalinski Journal: Radiother Oncol Date: 2010-04-27 Impact factor: 6.280
Authors: R Hughes; R Glynne-Jones; J Grainger; P Richman; A Makris; M Harrison; R Ashford; R A Harrison; J I Livingstone; P J McDonald; J Meyrick Thomas; I C Mitchell; J M A Northover; R Phillips; M Wallace; A Windsor; J R Novell Journal: Int J Colorectal Dis Date: 2005-04-30 Impact factor: 2.571
Authors: Andrew D Newton; Jiaqi Li; Arjun N Jeganathan; Najjia N Mahmoud; Andrew J Epstein; E Carter Paulson Journal: Dis Colon Rectum Date: 2016-08 Impact factor: 4.585
Authors: Thomas E Read; Jose E Andujar; Philip F Caushaj; Douglas R Johnston; David W Dietz; Robert J Myerson; James W Fleshman; Elisa H Birnbaum; Matthew G Mutch; Ira J Kodner Journal: Dis Colon Rectum Date: 2004-04-19 Impact factor: 4.585
Authors: Isabelle Bedrosian; Miguel A Rodriguez-Bigas; Barry Feig; Kelly K Hunt; Lee Ellis; Steven A Curley; Jean Nicolas Vauthey; Marc Delclos; Christopher Crane; Nora Janjan; John M Skibber Journal: J Gastrointest Surg Date: 2004-01 Impact factor: 3.452
Authors: Paola Germani; Francesca Di Candido; Daniel Léonard; Dajana Cuicchi; Ugo Elmore; Marco Ettore Allaix; Vittoria Pia Barbieri; Laura D'Allens; Seraina Faes; Marika Milani; Damiano Caputo; Carmen Martinez; Jan Grosek; Valerio Caracino; Niki Christou; Sapho X Roodbeen; Umberto Bracale; Aurelia Wildeboer; Antonella Usai; Michele Benedetti; Alessandro Balani; Giuseppe Piccinni; Marco Catarci; Paolo Millo; Nicole Bouvy; Francesco Corcione; Roel Hompes; Frédéric Ris; Massimo Basti; Ales Tomazic; Eduardo Targarona; Alessandro Coppola; Andrea Pietrabissa; Dieter Hahnloser; Michel Adamina; Massimo Viola; Mario Morino; Riccardo Rosati; Gilberto Poggioli; Alex Kartheuser; Antonino Spinelli; Nicolò de Manzini Journal: Updates Surg Date: 2021-04-05